We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Caffeine Shown to Block Cholesterol to Brain

By Biotechdaily staff writers
Posted on 29 Apr 2008
Daily intake of caffeine has been shown to block the deleterious effects of high cholesterol that scientists have linked to Alzheimer's disease. More...


A study slated to be published in the open access publication, Journal of Neuroinflammation revealed that caffeine equivalent to just one cup of coffee per day could protect the blood-brain barrier (BBB) from damage that occurred with a high-fat diet. The BBB protects the central nervous system from the rest of the body's circulation, providing the brain with its own controlled microenvironment. Earlier studies have demonstrated that high levels of cholesterol break down the BBB, which can then no longer protect the central nervous system from the damage caused by blood-borne contamination. BBB leakage occurs in a host of neurologic disorders such as Alzheimer's disease.

In this study, researchers from the University of North Dakota School of Medicine and Health Sciences (Grand Forks, USA) gave rabbits 3 mg caffeine each day--the equivalent of a daily cup of coffee for an average-sized person. The rabbits were fed a cholesterol-enriched diet during this time. After 12 weeks, a number of laboratory tests demonstrated that the BBB was significantly intact in rabbits receiving a daily dose of caffeine.

"Caffeine appears to block several of the disruptive effects of cholesterol that make the blood-brain barrier leaky,” reported Dr. Jonathan Geiger, from the University of North Dakota School of Medicine and Health Sciences. "High levels of cholesterol are a risk factor for Alzheimer's disease, perhaps by compromising the protective nature of the blood-brain barrier. For the first time we have shown that chronic ingestion of caffeine protects the BBB from cholesterol-induced leakage.”

Caffeine appears to protect BBB breakdown by maintaining the expression levels of tight junction proteins. These proteins bind the cells of the BBB tightly to each other to stop unwanted molecules crossing into the central nervous system. These findings validated and extend results from other studies showing that caffeine intake protects against memory loss in aging and in Alzheimer's disease.

"Caffeine is a safe and readily available drug and its ability to stabilize the blood-brain barrier means it could have an important part to play in therapies against neurological disorders,” stated Dr.Geiger.


Related Links:
University of North Dakota School of Medicine and Health Sciences

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
All-in-One Molecular System
AIO M160
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical Abstract (Ziegler, AG., Rewers, M.J., Achenbach, P. et al. Diabetologia (2026). https://doi.org/10.1007/s00125-026-06841-z)

International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes

Type 1 diabetes (T1D) is an autoimmune disease that can develop in childhood or adulthood and affects an estimated 9.5 million people worldwide. Its complications range from acute diabetic ketoacidosis... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.